logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12435117 B1

PDFFull Text
Date of Patent:
Oct. 07, 2025

Filed:

Mar. 27, 2020

Method for producing immune cells and use thereof

Applicant:

Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR;

Inventors:

Yee Sook Cho, Daejeon, KR;

Han-Seop Kim, Daejeon, KR;

Jae Yun Kim, Daejeon, KR;

Binna Seol, Daejeon, KR;

Assignee:

KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, Daejeon, KR;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Tracy Vivlemore

Assistant Examiner:

Fatimah Khalaf Matalkah

Int. Cl.
CPC ...
A61K 35/17 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/435 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4205 (2025.01); A61K 40/4211 (2025.01); A61K 40/4255 (2025.01); A61P 35/00 (2018.01); C07K 14/43504 (2013.01); C07K 14/4748 (2013.01); C07K 14/70503 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); C12N 5/0646 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2239/28 (2023.05); A61K 2239/38 (2023.05); A61K 2239/54 (2023.05); C12N 2501/125 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2318 (2013.01); C12N 2501/2321 (2013.01); C12N 2501/26 (2013.01); C12N 2501/60 (2013.01); C12N 2501/602 (2013.01); C12N 2501/603 (2013.01); C12N 2501/604 (2013.01); C12N 2501/606 (2013.01); C12N 2501/727 (2013.01);
Abstract

The present invention relates to: a method for producing immunocytes, specifically induced natural killer T (iNKT) cells that are induced by direct reprogramming of isolated somatic cells, and chimeric antigen receptor (CAR)-iNKT cells into which a CAR gene encoding a CAR is introduced; iNKT cells produced by the method; and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, comprising the iNKT cells. The method according to the present invention can produce, through direct reprogramming, iNKT cells or iNKT cells into which a CAR gene is introduced, from isolated cells so as to simplify the production process and shorten production time, thereby reducing costs, to have excellent NKT cell production efficiency, and to ensure safety according to the production without passing through induced pluripotent stem cells, thereby having an excellent NKT cell production effect distinguished from that of a conventional reprogramming technique. In addition, the iNKT cells or iNKT cells into which a CAR gene is introduced, which are produced by the method, have an excellent cancer cell killing ability, and thus can be effectively used as a cell therapy composition or a pharmaceutical composition for preventing or treating cancer.

Find Patent Forward Citations

Loading…